Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia
Authors
Krajnović, DušankaJocić, D.
Arsić, J.
Petrova, Guenka
Tadić, Ivana
Tasić, Ljiljana
Jocić-Milosavljević, B.
Conference object (Published version)
Metadata
Show full item recordAbstract
Objectives: To assess the knowledge of health professionals about epidemiological
and national regulatory issues concerning rare diseases (RD) and access to orphan
drugs. MethOds: This paper reports some of the results from an ongoing KAP
study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective
cross-sectional study was conducted from May to June 2013, on a convenient sample
of licensed pharmacists and physicians from two, large cities’ and its suburbies in
the central parts of RS. A specially designed KAP instrument in a form of three-part
questionnaire was applied and these results were related to the assessment of
concerning knowledge (8 multiple-choice questions) and self-assessment of the
participants (one question). Results: The study population included 214 health
workers (151 pharmacists and 63 physicians); the average age of participants was
40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority
of the part...icipants (57%) knew the true prevalence of RD and slightly less than third
of the samples (26.2%) responded correctly to the question of the extent of European
population suffering from RD. There are major differences in regulatory knowledge
about access to treatment for rare diseases, as participants answered correctly in
a wide range of 21% to 67.4%. Most of the health professionals self-estimated that
possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio-
logical and legislative issues concerning RD and orphan drugs. The average level of
overall knowledge assessment for all questions and self-assessmentin general was
3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents
estimated that possess less knowledge on RD (general information) and drugs to
treat RD, or insufficiently. The average level of respondents’ knowledge on RD and
drugs to treat RD was below the average.
Source:
Value in Health, 2013, 16, 7, A478-A478Publisher:
- Elsevier Inc.
Note:
- ISPOR 16th Annual European Congress and 4th Latin America Conference Research Abstracts
Collections
Institution/Community
PharmacyTY - CONF AU - Krajnović, Dušanka AU - Jocić, D. AU - Arsić, J. AU - Petrova, Guenka AU - Tadić, Ivana AU - Tasić, Ljiljana AU - Jocić-Milosavljević, B. PY - 2013 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1846 AB - Objectives: To assess the knowledge of health professionals about epidemiological and national regulatory issues concerning rare diseases (RD) and access to orphan drugs. MethOds: This paper reports some of the results from an ongoing KAP study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective cross-sectional study was conducted from May to June 2013, on a convenient sample of licensed pharmacists and physicians from two, large cities’ and its suburbies in the central parts of RS. A specially designed KAP instrument in a form of three-part questionnaire was applied and these results were related to the assessment of concerning knowledge (8 multiple-choice questions) and self-assessment of the participants (one question). Results: The study population included 214 health workers (151 pharmacists and 63 physicians); the average age of participants was 40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority of the participants (57%) knew the true prevalence of RD and slightly less than third of the samples (26.2%) responded correctly to the question of the extent of European population suffering from RD. There are major differences in regulatory knowledge about access to treatment for rare diseases, as participants answered correctly in a wide range of 21% to 67.4%. Most of the health professionals self-estimated that possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio- logical and legislative issues concerning RD and orphan drugs. The average level of overall knowledge assessment for all questions and self-assessmentin general was 3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents estimated that possess less knowledge on RD (general information) and drugs to treat RD, or insufficiently. The average level of respondents’ knowledge on RD and drugs to treat RD was below the average. PB - Elsevier Inc. C3 - Value in Health T1 - Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia VL - 16 IS - 7 SP - A478 EP - A478 DO - 10.1016/j.jval.2013.08.900 ER -
@conference{ author = "Krajnović, Dušanka and Jocić, D. and Arsić, J. and Petrova, Guenka and Tadić, Ivana and Tasić, Ljiljana and Jocić-Milosavljević, B.", year = "2013", abstract = "Objectives: To assess the knowledge of health professionals about epidemiological and national regulatory issues concerning rare diseases (RD) and access to orphan drugs. MethOds: This paper reports some of the results from an ongoing KAP study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective cross-sectional study was conducted from May to June 2013, on a convenient sample of licensed pharmacists and physicians from two, large cities’ and its suburbies in the central parts of RS. A specially designed KAP instrument in a form of three-part questionnaire was applied and these results were related to the assessment of concerning knowledge (8 multiple-choice questions) and self-assessment of the participants (one question). Results: The study population included 214 health workers (151 pharmacists and 63 physicians); the average age of participants was 40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority of the participants (57%) knew the true prevalence of RD and slightly less than third of the samples (26.2%) responded correctly to the question of the extent of European population suffering from RD. There are major differences in regulatory knowledge about access to treatment for rare diseases, as participants answered correctly in a wide range of 21% to 67.4%. Most of the health professionals self-estimated that possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio- logical and legislative issues concerning RD and orphan drugs. The average level of overall knowledge assessment for all questions and self-assessmentin general was 3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents estimated that possess less knowledge on RD (general information) and drugs to treat RD, or insufficiently. The average level of respondents’ knowledge on RD and drugs to treat RD was below the average.", publisher = "Elsevier Inc.", journal = "Value in Health", title = "Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia", volume = "16", number = "7", pages = "A478-A478", doi = "10.1016/j.jval.2013.08.900" }
Krajnović, D., Jocić, D., Arsić, J., Petrova, G., Tadić, I., Tasić, L.,& Jocić-Milosavljević, B.. (2013). Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia. in Value in Health Elsevier Inc.., 16(7), A478-A478. https://doi.org/10.1016/j.jval.2013.08.900
Krajnović D, Jocić D, Arsić J, Petrova G, Tadić I, Tasić L, Jocić-Milosavljević B. Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia. in Value in Health. 2013;16(7):A478-A478. doi:10.1016/j.jval.2013.08.900 .
Krajnović, Dušanka, Jocić, D., Arsić, J., Petrova, Guenka, Tadić, Ivana, Tasić, Ljiljana, Jocić-Milosavljević, B., "Regulatory and general epidemiological knowledge about rare diseases and access to treatment for rare diseases: health professionals' view in Serbia" in Value in Health, 16, no. 7 (2013):A478-A478, https://doi.org/10.1016/j.jval.2013.08.900 . .